Targeting nerve growth factor for pain relief: pros and cons

키워드

참고문헌 (87)

1. Levi-Montalcini R, "Essential role of the nerve growth factor in the survival and maintenance of dissociated sensory and sympathetic embryonic nerve cells in vitro", Dev Biol, 6, pp.653~659 (1963)
2. Chang DS, "Antinerve growth factor in pain management : current evidence", J Pain Res, 9, pp.373~383 (2016)
3. Yuan H, "Hypomethylation of nerve growth factor(NGF)promotes binding of C", EBPα and contributes to inflammatory hyperalgesia in rats, 2020, pp.17, 34~
4. Bennett DL, "Neurotrophic factors : important regulators of nociceptive function", Neuroscientist, 7, pp.13~17 (2001)
5. Hefti FF, "Novel class of pain drugs based on antagonism of NGF", Trends Pharmacol Sci, 27, pp.85~91 (2006)
6. Crowley C, "Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons", Cell, 76, pp.1001~1011 (1994)
7. Schmelz M, "Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic lowback pain : mechanism of action in the context of efficacy and safety", Pain, 160, pp.2210~2220 (2019)
8. Osikowicz M, "Inhibition of endogenous NGF degradation induces mechanical allodynia and thermal hyperalgesia in rats", Mol Pain, 9, pp.37~ (2013)
9. Price TJ, "Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse", J Pain, 8, pp.263~272 (2007)
10. Truzzi F, "Neurotrophins and their receptors stimulate melanoma cell proliferation and migration", J Invest Dermatol, 128, pp.2031~2040 (2008)
11. Ricci A, "Adenocarcinomas of the lung and neurotrophin system : a review", Biomedicines, 10, pp.2531~ (2022)
12. Hirose M, "NGF", TrkA signaling as a therapeutic target for pain, 2016, pp.16, 175~182
13. Wise BL, "The evolution of nerve growth factor inhibition in clinical medicine", Nat Rev Rheumatol, 17, pp.34~46 (2021)
14. Denk F, "Nerve growth factor and pain mechanisms", Annu Rev Neurosci, 40, pp.307~325 (2017)
15. Zhang X, "NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels", EMBO J, 24, pp.4211~4223 (2005)
16. Oo WM, "Nerve growth factor(NGF)inhibitors and related agents for chronic musculoskeletal pain : a comprehensive review", BioDrugs, 35, pp.611~641 (2021)
17. Barker PA, "Nerve growth factor signaling and its contribution to pain", J Pain Res, 13, pp.1223~1241 (2020)
18. Vera DB, "Role of mitochondria in interplay between NGF", TRKA, miR-145 and possible therapeutic strategies for epithelial ovarian cancer, 2021, pp.12, 8~
19. Iftinca M, "TRPV1-targeted drugs in development for human pain conditions", Drugs, 81, pp.7~27 (2021)
20. Shane Anderson A, "Why is osteoarthritis an age-related disease", Best Pract Res Clin Rheumatol, 24, pp.15~26 (2010)
21. Molloy NH, "Nerve growth factor in cancer cell death and survival", Cancers (Basel), 3, pp.510~530 (2011)
22. Seidel MF, "Nerve growth factor in rheumatic diseases", Semin Arthritis Rheum, 40, pp.109~126 (2010)
23. Banks BE, "Nerve growth factor has anti-inflammatory activity in the rat hindpaw oedema test", Neurosci Lett, 47, pp.41~45 (1984)
24. Gigante A, "Expression of NGF, Trka and p75 in human cartilage", Eur J Histochem, 47, pp.339~344 (2003)
25. Smeyne RJ, "Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk", NGF receptor gene, 1994, pp.368, 246~249
26. Schnitzer TJ, "A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee", Osteoarthritis Cartilage, 23(Suppl 1), pp.S8~S17 (2015)
27. McNamee KE, "Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain", Pain, 149, pp.386~392 (2010)
28. Voga M, "Articular cartilage regeneration in veterinary medicine", Adv Exp Med Biol, 1401, pp.23~55 (2022)
29. von Loga IS, "Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis", Ann Rheum Dis, 78, pp.672~675 (2019)
30. Aso K, "Effects of intraarticular injection of anti-nerve growth factor neutralizing antibody on pain in osteoarthritis rat", Int J Pain Relief, 4, pp.1~5 (2020)
31. Dakin P, "The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain : a phase IIb", III double-blind, placebo-controlled, randomized clinical trial, 2019, pp.71, 1824~1834
32. Miyagi M, "Efficacy of nerve growth factor antibody in a knee osteoarthritis pain model in mice", BMC Musculoskelet Disord, 18, pp.428~ (2017)
33. Xu L, "The anti-NGF antibody muMab 911both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain", Osteoarthritis Cartilage, 24, pp.1587~1595 (2016)
34. Majuta LA, "Anti-nerve growth factor therapy increases spontaneous day", night activity in mice with orthopedic surgery-induced pain, 2017, pp.158, 605~617
35. LaBranche TP, "Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model", Ann Rheum Dis, 76, pp.295~302 (2017)
36. Huang H, "Nerve growth factor induced after temporomandibular joint inflammation decelerates chondrocyte differentiation", Oral Dis, 19, pp.604~610 (2013)
37. Mammoto T, "Nerve growth factor improves ligament healing", J Orthop Res, 26, pp.957~964 (2008)
38. Pecchi E, "Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes : possible involvement in oa pain", Osteoarthritis Cartilage, 22, pp.S23~ (2014)
39. Johnson AC, "Critical evaluation of animal models of visceral pain for therapeutics development : a focus on irritable bowel syndrome", Neurogastroenterol Motil, 32, pp.e13776~ (2020)
40. Lane NE, "Osteoarthritis in 2016 : anti-NGF treatments for pain-two steps forward, one step back", Nat Rev Rheumatol, 13, pp.76~78 (2017)
41. Meng F, "Efficacy and safety of biologic agents for the treatment of osteoarthritis : a meta-analysis of randomized placebo-controlled trials", Ther Adv Musculoskelet Dis, 14, pp.1759720X221080377~ (2022)
42. Pallav M, "POS1126 clinical efficacy and safety of monoclonal antibody against nerve growth factor and fibroblast growth factor-18 therapy of osteoarthritis", Ann Rheum Dis, 81, pp.892~ (2022)
43. Leite VF, "Anti-nerve growth factor in the treatment of low back pain and radiculopathy : a systematic review and a meta-analysis", Pain Physician, 17, pp.E45~E60 (2014)
44. Markman JD, "Tanezumab for chronic low back pain : a randomized, double-blind, placebo-and active-controlled, phase 3 study of efficacy and safety", Pain, 161, pp.2068~2078 (2020)
45. Yang S, "The efficacy of nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain : a metaanalysis", Front Pharmacol, 11, pp.817~ (2020)
46. Katz N, "Efficacy and safety of tanezumab in the treatment of chronic low back pain", Pain, 152, pp.2248~2258 (2011)
47. Kivitz AJ, "Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain", Pain, 154, pp.1009~1021 (2013)
48. Reed NR, "Somatosensory behavioral alterations in a NGF-induced persistent low back pain model", Behav Brain Res, 418, pp.113617~ (2022)
50. Mai L, "Role of nerve growth factor in orofacial pain", J Pain Res, 13, pp.1875~1882 (2020)
51. Descamps S, "Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways", J Biol Chem, 276, pp.17864~17870 (2001)
52. Verbeke S, "Overexpression of p75(NTR)increases survival of breast cancer cells through p21(waf1)", Cell Signal, 22, pp.1864~1873 (2010)
53. Lin H, "Nerve growth factor regulates liver cancer cell polarity and motility", Mol Med Rep, 23, pp.288~ (2021)
54. Buehlmann D, "Prospective administration of anti-nerve growth factor treatment effectively suppresses functional connectivity alterations after cancer-induced bone pain in mice", Pain, 160, pp.151~159 (2019)
55. Sevcik MA, "Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization", Pain, 115, pp.128~141 (2005)
56. Jimenez-Andrade JM, "Preventive or late administration of anti-NGF therapy attenuates tumorinduced nerve sprouting, neuroma formation, and cancer pain", Pain, 152, pp.2564~2574 (2011)
57. Guedon JG, "Dissociation between the relief of skeletal pain behaviors and skin hypersensitivity in a model of bone cancer pain", Pain, 157, pp.1239~1247 (2016)
58. Jensen TS, "A new definition of neuropathic pain", Pain, 152, pp.2204~2205 (2011)
59. Foley KM, "Opioids and chronic neuropathic pain", N Engl J Med, 348, pp.1279~1281 (2003)
60. Cirillo G, "Intrathecal NGF administration reduces reactive astrocytosis and changes neurotrophin receptors expression pattern in a rat model of neuropathic pain", Cell Mol Neurobiol, 30, pp.51~62 (2010)
61. McArthur JC, "A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291", Neurology, 54, pp.1080~1088 (2000)
62. Schnitzer TJ, "Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip : a 16-week dose-titration study", Semin Arthritis Rheum, 50, pp.387~393 (2020)
63. Dai WL, "Suppression of peripheral NGF attenuates neuropathic pain induced by chronic constriction injury through the TAK1-MAPK", NF-κB signaling pathways, 2020, pp.18, 66~
64. Dos Reis RC, "Nerve growth factor induces facial heat hyperalgesia and plays a role in trigeminal neuropathic pain in rats", Behav Pharmacol, 27, pp.528~535 (2016)
65. Sainoh T, "Efficacy of anti-nerve growth factor therapy for discogenic neck pain in rats", Spine (Phila Pa 1976), 39, pp.E757~E762 (2014)
66. Jasim H, "Altered levels of salivary and plasma pain related markers in temporomandibular disorders", J Headache Pain, 21, pp.105~ (2020)
67. Alhilou AM, "Sex-related differences in response to masseteric injections of glutamate and nerve growth factor in healthy human participants", Sci Rep, 11, pp.13873~ (2021)
68. Gao Y, "Efficacy and safety of anti-nerve growth factor antibody therapy for hip and knee osteoarthritis : a meta-analysis", Orthop J Sports Med, 10, pp.23259671221088590~ (2022)
69. Rahmi, "Nerve growth factor and S100B : molecular marker of neuroregeneration after injection of freeze-dried platelet rich plasma", J Oral Biol Craniofac Res, 12, pp.570~574 (2022)
70. Boscato N, "Effect of standardized training in combination with masseter sensitization on corticomotor excitability in bruxer and control individuals : a proof of concept study", Sci Rep, 12, pp.17469~ (2022)
71. Ye Y, "Nerve growth factor links oral cancer progression, pain, and cachexia", Mol Cancer Ther, 10, pp.1667~1676 (2011)
72. Xu XJ, "Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome : a preliminary explorative study", Aliment Pharmacol Ther, 45, pp.100~114 (2017)
73. Coelho A, "Partners in crime : NGF and BDNF in visceral dysfunction", Curr Neuropharmacol, 17, pp.1021~1038 (2019)
74. Li Q, "Noninflammatory upregulation of nerve growth factor underlies gastric hypersensitivity induced by neonatal colon inflammation", Am J Physiol Regul Integr Comp Physiol, 310, pp.R235~R242 (2016)
75. Barker K, "Targeting pro-inflammatory mediators to treat visceral pain", pp.2022
76. Chen Y, "Electroacupuncture at ST36 relieves visceral hypersensitivity via the NGF", TrkA, J Inflamm Res, pp.2021, 14[DOI]
77. Regmi B, "Possible implications of animal models for the assessment of visceral pain", Animal Model Exp Med, 3, pp.215~228 (2020)
78. Liang D, "A study on the mechanism of electroacupuncture to alleviate visceral pain and NGF expression", Comput Intell Neurosci, 2022, pp.3755439~ (2022)
79. Jiao Y, "Propionibacterium acnes contributes to low back pain via upregulation of NGF in TLR2-NF-κB", JNK or ROS pathway, 2022, pp.24, 104980~
80. Rizzo RRN, "Targeting neurotrophic factors for low back pain and sciatica : a systematic review and meta-analysis", Rheumatology (Oxford), 61, pp.2243~2254 (2022)
81. Delivanoglou N, "Spatio-temporal expression profile of NGF and the two-receptor system, TrkA and p75NTR, in experimental autoimmune encephalomyelitis", J Neuroinflammation, 17, pp.41~ (2020)
82. Yeh JF, "Monoclonal antibodies for chronic pain : a practical review of mechanisms and clinical applications", Mol Pain, 13, pp.1744806917740233~ (2017)
83. Gwak YS, "Attenuation of spinal cord injury-induced hyperalgesia by administration of antibody to nerve growth factor in the rat", Korean J Pain, 16, pp.7~13 (2003)
84. El-Hashim AZ, "Nerve growth factor enhances cough via a central mechanism of action", Pharmacol Res, 74, pp.68~77 (2013)
85. Minnone G, "NGF and its receptors in the regulation of inflammatory response", Int J Mol Sci, 18, pp.1028~ (2017)
86. Brown MT, "Tanezumab reduces osteoarthritic knee pain: results of a randomized, doubleblind, placebo-controlled phase III trial", J Pain, 13, pp.790~798 (2012)
87. Bernard NJ, "NGF vaccine reduces pain", Nat Rev Rheumatol, 15, pp.251~ (2019)

관련 논문AI추천